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S U M M A R Y
Objectives: Infective endocarditis due to non-toxigenic Corynebacterium diphtheriae is uncommon; we
report 10 cases occurring over a 14-year period in Auckland, New Zealand and review the approach for
treatment.
Case series: Eight of the 10 patients had known prosthetic valves or homografts in situ. Three patients
required surgical intervention for infective endocarditis. Seven patients were treated with a combination
of b-lactam and aminoglycoside, and one each was treated with a combination of vancomycin and an
aminoglycoside, a b-lactam alone, and vancomycin alone. All patients survived and none relapsed.
Review of literature: The antibiotic treatment of 46 previously reported cases was reviewed; patients
treated with a b-lactam and aminoglycoside (n = 25), and without the addition of an aminoglycoside
(n = 11) were compared. The differences in length of treatment within each group make the comparison
of outcome (mortality, need for surgical intervention, disease and treatment complications) difﬁcult.
However, regardless of the length of treatment, there was no difference in mortality or need for surgical
intervention between the two groups in the currently published cases.
Conclusions: Current evidence suggests that endocarditis of either native or prosthetic valves, caused by
penicillin-susceptible C. diphtheriae, demonstrates a favorable outcome when treated with either a b-
lactam alone or in combination with an aminoglycoside. Patient-speciﬁc factors will determine which
approach is more appropriate for each individual patient.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Corynebacterium diphtheriae was ﬁrst described in 1884 by
Loefﬂer as the causative agent of diphtheria.1 The ﬁrst case of
infective endocarditis caused by this organism was reported in
1893.2 C. diphtheriae is an uncommon cause of endocarditis,
mycotic aneurysm, septic arthritis, splenic abscess, and osteomy-
elitis.2–27 However, reports of infective endocarditis due to non-
toxigenic strains have been increasing in the literature of late, with
63 of the 76 reported cases reported after 1980.2,6
C. diphtheriae endocarditis has been described as an aggressive
disease requiring urgent surgical intervention, especially in those
with prosthetic valves.2 Most patients with C. diphtheriae
endocarditis have underlying cardiac disease, prosthetic valves,
or a history of intravenous drug use.2 Recommendations for
treatment based on expert opinion suggest that 4–6 weeks of a b-* Corresponding author. Tel.: +64 9 3074949x2044; fax: +64 9 3074940.
E-mail address: sharmini.muttaiyah@uqconnect.edu.au (S. Muttaiyah).
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doi:10.1016/j.ijid.2011.04.003lactam antibiotic in conjunction with an aminoglycoside be
given.28
Ten cases of C. diphtheriae endocarditis from two hospitals in
Auckland, New Zealand occurring over a 14-year period are
reported, and the outcome of treatment for published cases of
endocarditis, in particular the beneﬁt of combination therapy with
a b-lactam and aminoglycoside, is reviewed.
2. Methods
2.1. Case series
In the present study, the medical notes of patients with C.
diphtheriae infection identiﬁed from the Microbiology Department
records at Auckland City Hospital and Middlemore Hospital were
reviewed. Patients included had to have had C. diphtheriae isolated
from one or more sets of blood cultures, isolated from cardiac valve
tissue, or C. diphtheriae DNA detected by 16S rDNA PCR from
cardiac valve tissue. Cases met the deﬁnition of deﬁnite or possible
infective endocarditis as determined by the Modiﬁed Duke Criteria
for Endocarditis.29ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Clinical features and outcome of patients with Corynebacterium diphtheriae endocarditis in this report (n = 10)
Patient
No.
Age (years)/
sex
Biotype/penicillin
MIC
Risk factors Antibiotics (duration) Surgery Complications
(disease or treatment)
Outcome
1 12/F NA Tetralogy of Fallot
Prosthetic AV
Vancomycin (4 weeks) No Neutropenia
(treatment)
Survived
2 12/F gravis/0.25 mg/l Rheumatic fever
Prosthetic AV and MV
Penicillin (6 weeks)
Gentamicin (2 weeks)
Yes Nil Survived
3 9/M gravis/NA Congenital MR
Prosthetic MV
Ceftriaxone (6 weeks)
Gentamicin (6 weeks)
No Nil Survived
4 4/F gravis/NA Hypoplastic left heart Penicillin (4 weeks)
Gentamicin (4 weeks)
No Macular rash (treatment)
Neutropenia (treatment)
Renal tubular damage
(treatment)
Survived
5 28/M gravis/0.25 mg/l Transposition of the
great arteries
Aortic homograft
Penicillin (6 weeks)
Gentamicin (6 weeks)
No Nil Survived
6 62/M gravis/0.25 mg/l Nil Penicillin (4 weeks)
Gentamicin (2 weeks)
No Nil Survived
7 10/M gravis/NA (identiﬁed
through sequencing;
no culture isolate)
Nil Amoxicillin (5 weeks pre-op)
Vancomycin (5 weeks)
Gentamicin (5 weeks)
Amoxicillin (2 weeks post-op)
Vancomycin (2 weeks)
Amikacin (2 weeks)
Yes Congestive cardiac failure
(disease)
Survived
8 57/F gravis/0.25 mg/l Rheumatic fever with MR
Prosthetic MV
Vancomycin (6 weeks)
Gentamicin (2 weeks)
No Nil Survived
9 5/F gravis/0.5 mg/l Congenital VSD Penicillin (6 weeks)
Gentamicin (2 weeks)
No Osteomyelitis – calcaneum
(disease)
Renal and cerebral infarction
Survived
10 28/M NA/NA Rheumatic fever with
prosthetic MV and AV
Penicillin (5 weeks)
Gentamicin (5 weeks)
Yes Pleural effusion (treatment) Survived
AV, aortic valve; F, female; M, male; MIC, minimum inhibitory concentration; MR, mitral regurgitation; MV, mitral valve; NA, not available; VSD, ventricular septal defect.
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in patients with different antibiotic regimes using GraphPad Instat
software and employing the Fisher’s exact test.
Ethical approval for the study was provided by the Northern
Region X Ethics Committee.
2.2. Literature review
In addition to the cases reported, a Medline search (MESH terms
‘Corynebacterium diphtheriae endocarditis’ English literature) was
performed to identify cases of C. diphtheriae endocarditis reported
in the literature. Cases were accepted where information regarding
the demographics, clinical outcomes, and treatment was provided.
3. Results
3.1. Case series
Ten patients with C. diphtheriae endocarditis from 1994 to 2007
were identiﬁed. Table 1 summarizes the demographics, clinical
features, treatment, and outcome of these cases. Modiﬁed Duke
criteria were complete for deﬁnite (n = 6) or possible (n = 4)
infective endocarditis in all cases.
3.2. Literature review
A Medline search (MESH terms ‘Corynebacterium diphtheriae
endocarditis’ English literature) identiﬁed 76 cases of infective
endocarditis caused by C. diphtheriae.2,24,27 Seventy of these cases
have been reviewed extensively elsewhere.2 Treatment data were
available for 46 of these cases.2,27 Twenty-nine of the 46 cases
received either b-lactam monotherapy (n = 11) or a b-lactam with
an aminoglycoside (n = 18); these cases are summarized in Tables
2 and 3, respectively. Five cases received b-lactam and aminogly-
coside with a third antimicrobial agent active against C.diphtheriae: vancomycin (n = 3), erythromycin (n = 1), and rifam-
pin (n = 1). These ﬁve cases were excluded from further analysis. Of
the remaining 12 cases, nine received a b-lactam with a non-
aminoglycoside agent: chloramphenicol (n = 3),19,20 vancomycin
(n = 3),16,18,24 erythromycin (n = 1),11 trimethoprim–sulfamethox-
azole (n = 1),20 and doxycycline and rifampin (n = 1),22 and three
were treated with non-b-lactam regimens: erythromycin,8,27
clindamycin–ciproﬂoxacin combination therapy,27 and sulphapyr-
idine.19,21
Treatment duration was available for 29 cases and mostly
ranged from 4 to 8 weeks (18 of 29), but longer durations have
been reported.19
There are no recommended guidelines for the treatment of
infective endocarditis caused by C. diphtheriae. Therapy in reported
cases has varied depending on local practice. The 11 cases who
received b-lactam only (Table 2) and the 25 cases who received b-
lactam and aminoglycoside (Table 1, n = 7/10 and Table 3, n = 18/
23), were compared for patient outcomes. Four patients died in
both groups (p = 0.39) and there was no signiﬁcant difference in
the number of patients requiring surgical intervention (p = 0.62).
No relapses were reported in either group.
4. Discussion
This case series of C. diphtheriae endocarditis demonstrates a
number of similarities with the 76 previously published cases and
the species-speciﬁc risk factors recently identiﬁed for Corynebac-
terium endocarditis.30 Firstly, all cases but two were caused by
non-toxigenic strains of C. diphtheriae biotype gravis. Secondly, the
median age was 12 years (range 4–62 years). This is in keeping
with previous cases, of which approximately 80% occurred in
patients aged less than 30 years. Thirdly, eight patients had pre-
existing cardiac abnormalities with prosthetic valves or homo-
grafts in situ. Cardiac abnormalities, including congenital cardiac
anomalies and prosthetic heart valves have been described as risk
Table 2
Cases of Corynebacterium diphtheriae endocarditis treated with a b-lactam alone (n = 11)
Year Ref. Age (years)/
sex
Biotype (toxin) Risk factors Echo Antibiotics (duration) Surgery Complications Outcome
1976 Van der Horst
et al.4
11/M gravis Nil NA Penicillin (1 day) No Peripheral embolism,
pulmonary edema
Died
1981 Love et al.5 16/M gravis MV prolapse NA Penicillin (7.5 weeks) Yes Ruptured cerebral
aneurysm, peripheral
emboli
Survived
1982 Sandler6 22/M gravis CHD NA Penicillin (NA) No Nil Survived
1983 Sirisanthana and
Sirisanthana3
13/F gravis VSD NA Penicillin (4 weeks) No Nil Survived
1993 Tiley et al.7 25/M gravis IVDU TV veg Penicillin (4 weeks) No Nil Survived
1998 Gubler et al.8 45/M mitis IVDU, AV AR pros veg Penicillin (NA) No Annular abscess,
septic shock
Died
1998 Gubler et al.8 19/F mitis Nil Possible Penicillin (NA) No Nil Survived
1998 Gubler et al.8 29/M mitis IVDU, bicuspid
AV, HIV-positive
Veg AV, leaﬂet
perforation
Penicillin (NA) No Annular abscess Died
2003 Lolekha et al.9 11/M NA (pos) CHD NA Penicillin (NA) No Cerebral hemorrhage
requiring evacuation
Died
2005 Mishra et al.2 26/F gravis MR MV veg Penicillin (1 week)
Ceftriaxone (9 weeks)
Yes Pulmonary edema Survived
2005 Mishra et al.2 21/M gravis MV prolapse MR, MV veg Penicillin (6 weeks) No Intracranial hemorrhage,
mycotic aneurysm, deep
vein thrombosis
Survived
AR, aortic regurgitation; AV, aortic valve; CHD, congenital heart disease; F, female; IVDU, intravenous drug user; M, male; MR, mitral regurgitation; MV, mitral valve; NA, not
available; pros, prosthesis; TV, tricuspid valve; veg, vegetation; VSD, ventricular septal defect.
Table 3
Cases of Corynebacterium diphtheria endocarditis treated with a b-lactam and an aminoglycoside (n = 18)
Year Ref. Age (years)/
sex
Biotype
(toxin)
Risk
factors
Echo Antibiotics
(duration)
Surgery Complications Outcome
1950 Almklov and Hansen10 8/F intermedius
(pos)
RHD NA Penicillin (3 months)
Streptomycin (16 days)
No Nil Survived
1976 Davidson et al.11 4/F mitis (pos) CHD NA Penicillin (6 weeks)
Streptomycin (6 weeks)
No Nil Survived
1993 Lortholary et al.13 5/M NA Nil NA Penicillin (NA)
Aminoglycoside (NA)
Metronidazole (NA)
NA Peripheral
embolism
Survived
1993 Lortholary et al.13 19/M NA Nil NA Penicillin (NA)
Aminoglycoside (NA)
NA Peripheral
embolism
Survived
1993 Lortholary et al.13 14/M NA VSD NA Ampicillin (NA)
Aminoglycoside (NA)
NA Nil Survived
1993 Lortholary et al.13 6/M NA VSD, AR NA Ampicillin (NA)
Aminoglycoside (NA)
NA Nil Survived
1985 Sirinavin and
Suthas-Na-Ayuthaya13
6/F NA VSD NA Penicillin (1 week)
Cephalothin (2 weeks)
Gentamicin (2 weeks)
No Nil Survived
1993 Tiley et al.7 22/F gravis MV prosthesis NAD Penicillin (6 weeks)
Gentamicin (6 weeks)
No Septic arthritis Survived
1993 Tiley et al.7 12/M gravis Nil MV veg Penicillin (2 days)
Flucloxacillin (2 days)
Gentamicin (2 days)
No Multiple emboli Died
1993 Tiley et al.7 28/F gravis Nil AV veg Penicillin (6 weeks)
Gentamicin (6 weeks)
No Septic arthritis Survived
1994 Lin et al.14 55/M NA AV prosthesis AV pros veg Penicillin (NA)
Cloxacillin (NA)
Gentamicin (NA)
No Cerebral
embolism
CVA
Died
1994 Lin et al.14 55/M NA AV prosthesis AV pros veg Penicillin (NA)
Cloxacillin (NA)
Gentamicin (NA)
No Cerebral
embolism
CVA
Died
1994 Lin et al.14 42/M gravis VSD, AR NA Penicillin (NA)
Gentamicin (NA)
No Septic shock Died
1995 Booth et al.15 20/M mitis Nil AR, MR, large
veg AV, MV
Penicillin (7 weeks)
Netilmicin (7 weeks)
Yes Coronary artery
embolism
CVA
Survived
1996 Hogg et al.17 38/M gravis Bicuspid AV Moderate
AR, veg
Ceftriaxone (NA)
Gentamicin (NA)
Metronidazole (NA)
Yes Septic arthritis Survived
1996 Hogg et al.17 43/M gravis NA NA Amoxicillin (3 weeks)
Gentamicin (3 weeks)
No Cerebral embolism
Mycotic aneurysm
Survived
2005 Mishra et al.2 33/M gravis Bicuspid AV MV mobile veg Penicillin (6 weeks)
Gentamicin (6 weeks)
Yes Pulmonary edema Survived
2005 Mishra et al.2 22/M gravis Nil MV veg Penicillin (6 weeks)
Gentamicin (3 weeks)
Flucloxacillin (3 weeks)
No Septic arthritis
Osteomyelitis
Survived
AR, aortic regurgitation; AV, aortic valve; CHD, congenital heart disease; CVA, cerebrovascular accident; F, female; M, male; MR, mitral regurgitation; MV, mitral valve; NA,
not available; NAD, No abnormality detected; pros, prosthesis; RHD, rheumatic heart disease; veg, vegetation; VSD, ventricular septal defect.
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cases in the literature were treated conservatively with only 18%
requiring surgery and in our cohort only three of 10 patients
required surgical intervention due to valvular dysfunction.
Despite these similarities, the mortality rate was much lower
than reported in other series;30 no patients in our series died. The
mortality rate in the 76 reported cases is 38% (29/76). The reasons
for this difference are uncertain, but this may be due to younger
aged patients, lower rates of nosocomial acquisition, and the time
period (1996–2007) in which our patients had their infection.
Increased clinical expertise in the management of endocarditis and
advances in cardiac imaging may also have contributed to better
outcomes.
C. diphtheriae endocarditis has been described as an aggressive
and destructive disease, similar to Staphylococcus aureus endocar-
ditis, with a high rate of complications, especially in patients with
underlying prosthetic valves.2 In this limited review, we did not
ﬁnd any signiﬁcant differences in complication rates (surgery,
relapse, or mortality rates) between those receiving an aminogly-
coside and b-lactam compared to those receiving a b-lactam alone.
Combination antimicrobial therapy, usually an aminoglycoside
and b-lactam antibiotic, is usually advocated for severe infections
such as endocarditis. The antimicrobial agents are chosen because
in combination they are said to be synergistic. The evidence for
synergy comes from in vitro assays, time–kill study or checker-
board (synergy) test, and animal models. The in vitro assays used to
evaluate drug–drug interactions are not standardized and have not
fully been evaluated in experimental and clinical settings.31 The
evidence supporting in vitro synergy between penicillin and
aminoglycosides for C. diphtheriae and other Corynebacterium spp is
limited. A single case report showed no reduction in penicillin
minimum inhibitory concentration (MIC) or minimum bactericidal
concentration (MBC) with the addition of netilmicin, but faster
killing was seen with combination therapy on a time–kill curve.15
A further case report describes in vitro synergism between
penicillin and gentamicin against C. diphtheriae, but the method
used was not described.32 A study looking at time–kill curves for
tobramycin, penicillin, and vancomycin for three strains of
Corynebacterium pseudodiphtheriticum showed 100% killing at 4,
8, and 24 h, respectively.33 No antimicrobial combinations were
tested. Another study looking at a penicillin-susceptible strain of
Corynebacterium jeikeium did show synergy with gentamicin and
penicillin combination at 96 h, but there was less than log101
difference in bacterial titers at 20 h between penicillin alone and
penicillin and gentamicin combination.34
The evidence from animal models for Corynebacterium
endocarditis is even less. A study looking at the in vitro activity
of amoxicillin in a non-toxigenic C. diphtheriae rabbit endocarditis
model showed a log104 reduction in bacterial titer over 3 days.35
Decisions regarding medical treatment of C. diphtheriae
endocarditis have been hampered in the past by a lack of criteria
for C. diphtheriae susceptibility testing and interpretation. The
Clinical and Laboratory Standards Institute (CLSI) published
interpretive criteria in 2006; a penicillin MIC of 1 mg/l is
considered susceptible.36 Susceptibility testing of C. diphtheriae is
not always performed, but studies report a penicillin MIC90 of
0.23 mg/l, well below the cut-off for susceptible.34,37,38 This
compares with the MIC90 of penicillin for Enterococcus faecalis of
3 mg/l, viridans streptococci of 1 mg/l, Streptococcus agalactiae of
0.12 mg/l, and Streptococcus pyogenes of 0.06 mg/l.39,40 The
penicillin MIC was determined for ﬁve isolates: 0.25 mg/l (n = 4)
and 0.5 mg/l (n = 1).
The combination of an aminoglycoside with a b-lactam has
been shown to exhibit partial or full synergy against Enterococcus
spp and alpha-hemolytic streptococci, and for this reason,
combination therapy is often recommended for the treatment ofother causes of bacterial endocarditis despite limited clinical data
regarding its efﬁcacy.39,40 A recent meta-analysis of available
comparative clinical trials regarding the role of aminoglycosides in
combination with a b-lactam for the treatment of bacterial
endocarditis caused by Gram-positive cocci, did not ﬁnd sufﬁcient
evidence to support the addition of an aminoglycoside to b-lactam
when treating patients with endocarditis.41 The use of low-dose
aminoglycoside in conjunction with a b-lactam to treat S. aureus
native valve endocarditis is also being questioned due to the
limited supporting data and risk of nephrotoxicity seen with such
an approach.42
This review has a number of limitations. Firstly, it is a
retrospective review of local experience and published cases, with
inherent difﬁculties in getting complete data. Secondly, the
duration of treatment was not adjusted for when comparing the
monotherapy group with the combination therapy group; the
majority of patients received 4–8 weeks of treatment, but some
receiving combination therapy received this for only part of the
treatment duration. Finally, this review was not sufﬁciently
powered to demonstrate non-inferiority of monotherapy com-
pared to combination therapy. Whilst acknowledging these
limitations, we can surmise that currently published cases do
not demonstrate a difference in the need for surgical intervention
or mortality rate between the two groups. Given the favorable
outcome in most patients regardless of therapeutic approach, it
also appears that C. diphtheriae endocarditis may be less of an
aggressive and destructive disease than previously thought.
C. diphtheriae endocarditis is uncommon and there are no
recommended guidelines for its treatment, nor are there likely to
be clinical trials comparing b-lactam monotherapy with b-lactam
and aminoglycoside combination. We agree with the concerns
raised by others that the additional beneﬁts of an aminoglycoside
may be marginal,43 and such beneﬁts should be weighed against
the risk of toxicity with prolonged aminoglycoside therapy.42 C.
diphtheriae endocarditis has been successfully treated with b-
lactam antibiotic alone, or in combination with an aminoglycoside.
Patient-speciﬁc factors should be considered when deciding which
approach to take: age, preexisting renal impairment, or ototoxicity
may favor the use of monotherapy.
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